TR200102500T2 - Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler. - Google Patents

Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.

Info

Publication number
TR200102500T2
TR200102500T2 TR2001/02500T TR200102500T TR200102500T2 TR 200102500 T2 TR200102500 T2 TR 200102500T2 TR 2001/02500 T TR2001/02500 T TR 2001/02500T TR 200102500 T TR200102500 T TR 200102500T TR 200102500 T2 TR200102500 T2 TR 200102500T2
Authority
TR
Turkey
Prior art keywords
polypeptides
chlamydia infection
dna sequences
bracelets
treat chlamydia
Prior art date
Application number
TR2001/02500T
Other languages
English (en)
Inventor
Probst Peter
Bhatia Ajay
A. W. Skeiky Yasir
P. Fling Steven
Jen Shyian
Jean Stromberg Erica
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/208,277 external-priority patent/US6166177A/en
Priority claimed from US09/288,594 external-priority patent/US6447779B1/en
Priority claimed from US09/410,568 external-priority patent/US6555115B1/en
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of TR200102500T2 publication Critical patent/TR200102500T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Chlamydia enfeksiyonunun teçhis ve tedavisi için bileçikler ve yöntemler aç klanmaktad r. Sunulan bileçikler aras nda, bir Chlamydia antijeninin en az bir antijenik k sm n içeren polipeptitler ve bu polipeptitleri kodlayan DNA dizileri yer al r. Bu polipeptitleri veya DNA dizilerini içeren farmasötik bileçimler ve aç lar n yan s ra bu polipeptitlere yönelik antikorlar da sunulmaktad r. Bu polipeptitleri veya DNA dizilerini ve uygun bir saptama reajan n içeren teçhis malzemesi tak mlar da hastalarda ve biyolojik örneklerde Chlamydia enfeksiyonunun tespiti için kullan labilir.
TR2001/02500T 1998-12-08 1999-12-08 Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler. TR200102500T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/208,277 US6166177A (en) 1998-12-08 1998-12-08 Compounds and methods for the treatment and diagnosis of chlamydial infection
US09/288,594 US6447779B1 (en) 1998-12-08 1999-04-08 Compounds for the diagnosis of Chlamydial infection
US09/410,568 US6555115B1 (en) 1998-12-08 1999-10-01 Compounds and methods for treatment and diagnosis of chlamydial infection
US42657199A 1999-10-22 1999-10-22

Publications (1)

Publication Number Publication Date
TR200102500T2 true TR200102500T2 (tr) 2002-03-21

Family

ID=27498718

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02500T TR200102500T2 (tr) 1998-12-08 1999-12-08 Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.

Country Status (18)

Country Link
EP (5) EP2277893A3 (tr)
JP (2) JP2002531129A (tr)
KR (4) KR20070108263A (tr)
CN (1) CN100365120C (tr)
AT (1) ATE469222T1 (tr)
AU (2) AU769293B2 (tr)
BR (1) BR9916020A (tr)
CA (2) CA2746535A1 (tr)
DE (1) DE69942426D1 (tr)
ES (1) ES2346832T3 (tr)
HK (1) HK1044020B (tr)
HU (1) HUP0400719A3 (tr)
IL (5) IL143531A0 (tr)
MX (1) MXPA01005813A (tr)
NO (2) NO20012812L (tr)
NZ (1) NZ512246A (tr)
TR (1) TR200102500T2 (tr)
WO (1) WO2000034483A2 (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
AU754122B2 (en) * 1998-04-20 2002-11-07 State of Oregon, acting by and through The State Board Of Higher Education, on behalf of Oregon State University, The Chlamydia proteins and their uses
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
AU769293B2 (en) 1998-12-08 2004-01-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1140998B1 (en) 1998-12-28 2008-01-23 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1163342B1 (en) 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2414884A1 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB2378056A (en) * 2001-07-27 2003-01-29 William Dixon Electrical connection device
EP2168596B1 (en) * 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
JP2004261017A (ja) * 2003-02-27 2004-09-24 Arkray Inc クラミジア・トラコマティスの検出方法およびそのためのキット
BRPI0609547A2 (pt) * 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
EP2068916A1 (en) * 2006-10-04 2009-06-17 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
WO2008156729A2 (en) * 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
CN102918155B (zh) * 2010-03-23 2015-12-16 和光纯药工业株式会社 沙眼衣原体检测用引物和探针、以及使用该引物和探针的沙眼衣原体的检测方法
CN109563481B (zh) * 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
EP0792365A1 (en) * 1994-11-17 1997-09-03 Maxim Pharmaceuticals Immunogens for stimulating mucosal immunity
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2220530A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. Improved method for obtaining full-length cdna sequences
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
EP0915978B1 (en) * 1996-07-12 2005-12-14 University of Manitoba Dna immunization against chlamydia infection
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
EP2218732A1 (en) * 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO2000011183A2 (en) * 1998-08-20 2000-03-02 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
AU769293B2 (en) 1998-12-08 2004-01-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1246935B1 (en) * 1999-09-28 2013-08-14 Geneohm Sciences Canada Inc. Highly conserved genes and their use to generate probes and primers for detection of microorganisms
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US9103184B2 (en) 2013-03-08 2015-08-11 Tejas Research & Engineering, Llc Inflow control valve
TWI710575B (zh) 2014-08-11 2020-11-21 德商第一三共歐洲公司 人類抗-fgfr4抗體

Also Published As

Publication number Publication date
CN100365120C (zh) 2008-01-30
HK1044020B (zh) 2008-10-31
AU2004201702B2 (en) 2007-07-05
KR20010101152A (ko) 2001-11-14
KR20100132086A (ko) 2010-12-16
CN1333832A (zh) 2002-01-30
IL209115A0 (en) 2011-01-31
HUP0400719A2 (hu) 2004-07-28
MXPA01005813A (es) 2002-05-06
DE69942426D1 (de) 2010-07-08
JP2002531129A (ja) 2002-09-24
EP1144642B1 (en) 2010-05-26
EP2277893A3 (en) 2011-03-30
IL143531A0 (en) 2002-04-21
NO20012812L (no) 2001-08-02
EP2223935A2 (en) 2010-09-01
NZ512246A (en) 2003-12-19
NO20101293L (no) 2001-08-02
JP2011036258A (ja) 2011-02-24
IL209114A0 (en) 2011-01-31
ES2346832T3 (es) 2010-10-20
EP2218733A1 (en) 2010-08-18
EP1144642A2 (en) 2001-10-17
WO2000034483A2 (en) 2000-06-15
HUP0400719A3 (en) 2010-08-30
WO2000034483A9 (en) 2001-07-05
EP2277892A2 (en) 2011-01-26
AU1935800A (en) 2000-06-26
CA2746535A1 (en) 2000-06-15
BR9916020A (pt) 2002-01-22
KR100829407B1 (ko) 2008-05-15
ATE469222T1 (de) 2010-06-15
EP2277892A3 (en) 2011-04-27
IL209116A0 (en) 2011-01-31
EP2277893A2 (en) 2011-01-26
IL209113A0 (en) 2011-01-31
AU2004201702A1 (en) 2004-05-20
AU769293B2 (en) 2004-01-22
PL363147A1 (en) 2004-11-15
CA2354232A1 (en) 2000-06-15
NO20012812D0 (no) 2001-06-07
HK1044020A1 (zh) 2002-10-04
EP2223935A3 (en) 2010-11-24
WO2000034483A3 (en) 2001-11-01
KR20070108263A (ko) 2007-11-08
KR20090088972A (ko) 2009-08-20

Similar Documents

Publication Publication Date Title
NO20030252L (no) Forbindelser og fremgangsmåter for behandling og diagnostikk av klamydiainfeksjon
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
NO20012812L (no) Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU2001255596A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
TR199901569T2 (tr) Tüberkülozun teshisi için bilesikler ve yöntemler.
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DK0784703T3 (da) Lamininkæder: Diagnostisk og terapeutisk anvendelse
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
ATE349533T1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
ATE166395T1 (de) Für c.difficile spezifische oligonukleotide
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection